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CLINICAL STUDIES Acute Coronary Syndromes
Temporal Increases in Plasma Markers of
Oxidized Low-Density Lipoprotein Strongly
Reflect the Presence of Acute Coronary Syndromes
Sotirios Tsimikas, MD, FACC,* Claes Bergmark, MD,† Reinaldo W. Beyer, MD, FACC,* Raj Patel, MD,*
Jennifer Pattison, BS,* Elizabeth Miller, BS,* Joseph Juliano, BS,* Joseph L. Witztum, MD*
La Jolla, California; and Stockholm, Sweden
OBJECTIVES This study was conducted to test the hypothesis that plasma markers of oxidized low-density
lipoprotein (OxLDL) reflect acute coronary syndromes (ACS).
BACKGROUND Oxidized LDL contributes to the pathogenesis of atherosclerosis, but its role in ACS is not
established.
METHODS Serial plasma samples were prospectively obtained from patients with an acute myocardial
infarction (MI) (n 8), unstable angina (UA) (n 15), stable coronary artery disease (CAD)
(n  17), angiographically normal coronary arteries (n  8), and from healthy subjects (n 
18), at entry into the study, hospital discharge (MI group only), and at 30, 120, and 210 days.
Chemiluminescent enzyme-linked immunosorbent assay was used to quantitate plasma levels
of: 1) immunoglobulin (Ig)M and IgG OxLDL autoantibody titers (presented as a mean
OxLDL autoantibody titer by averaging the results of four distinct epitopes); 2) LDL-
autoantibody immune complexes (LDL-IC); and 3) minimally OxLDL measured by
antibody E06 (OxLDL-E06), as determined by the content of oxidized phospholipids
(OxPL) per apolipoprotein B-100.
RESULTS Baseline OxLDL IgG autoantibody levels were higher in the MI group (p  0.0001). At
30-day follow-up, the mean IgM OxLDL titers increased by 48% (p  0.001) and 20% (p
 0.001), and IgM LDL-IC increased by 60% (p 0.01) and 26% (p 0.01) in the MI and
UA groups, respectively. The OxLDL-E06 levels increased by 54% (p  0.01) in the MI
group at hospital discharge and by 36% at 30 days. No significant changes in any OxLDL
markers were noted in the other groups. The OxLDL-E06 levels strongly paralleled the acute
rise in lipoprotein(a), or Lp(a), in the MI group, suggesting that toxic OxPL are preferentially
bound to Lp(a). Oxidized LDL-E06 also correlated extremely well with Lp(a) in the entire
cohort of patients (r  0.91, p  0.0001).
CONCLUSIONS Circulating OxLDL-specific markers strongly reflect the presence of ACS, implying immune
awareness to newly exposed oxidation-specific epitopes and possible release of OxLDL in the
circulation. The OxLDL-E06 measurements provide novel insights into plaque rupture and
the potential atherogenicity of Lp(a). (J Am Coll Cardiol 2003;41:360–70) © 2003 by the
American College of Cardiology Foundation
Oxidized low-density lipoprotein (OxLDL) is a critical
factor in the initiation and progression of atherosclerosis
and contributes to endothelial dysfunction and plaque de-
stabilization through multiple mechanisms (1–3). Ruptured
plaques are rich in lipids, which usually occupy more than
40% of plaque volume (4). Human studies have confirmed
that OxLDL and oxidized lipid byproducts are present
within atherosclerotic plaques (reviewed in Witztum and
Steinberg [5]). Presumably, these oxidized lipids are derived
from OxLDL and, in part, from degraded foam cells that
have released their contents into the atheromatous core.
Oxidized low-density lipoprotein (LDL) within atheroscle-
rotic lesions can be quantified and imaged by uptake of
intravenously injected, radiolabeled, oxidation-specific anti-
bodies (6) and is preferentially depleted in atherosclerotic
mouse and rabbit aortas following a dietary regression/
antioxidant intervention (7,8) and in carotid plaques of
patients treated with pravastatin (9).
The immune system plays an important role in athero-
sclerosis by both humoral and cell-mediated mechanisms.
T-lymphocytes isolated from whole blood in patients with
acute coronary syndromes (ACS) or harvested from human
carotid plaques have been shown to specifically recognize
OxLDL and proliferate when exposed to OxLDL (10).
Oxidized LDL is highly immunogenic and induces autoan-
tibody formation to a variety of oxidation-specific neo-
epitopes generated when LDL undergoes oxidation. Animal
studies have shown that OxLDL autoantibody titers reflect
isoprostane levels and the extent of atherosclerosis in apo-
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lipoprotein (apo) E/ or 12/15-lipoxygenase-deficient
mice (11) and accurately reflect depletion of OxLDL in
lesions of LDLR/ mice subjected to regression diets and
antioxidants (12). Considerable data on specific human
populations with stable disease suggest that elevated titers of
OxLDL autoantibodies have diagnostic and prognostic
value in determining the presence or extent of atheroscle-
rosis (13).
The role of OxLDL in ACS, however, has not been fully
established in humans. This study was designed to deter-
mine whether indirect (autoantibodies and LDL-immune
complex [IC]) or direct measures (OxLDL measured by
antibody E06 [OxLDL-E06]) of OxLDL would reflect
ACS, a setting in which plaque rupture/disruption is known
to occur.
METHODS
Study subjects. This study was performed at UCSD Med-
ical Center/Thornton Hospital and the UCSD Clinical
Research Center and was approved by the UCSD Institu-
tional Review Board. Patients were enrolled prospectively
with acute myocardial infarction (MI ) (n  8), unstable
angina (UA) (n  15) with Braunwald classification II or
III, stable coronary artery disease (CAD) (n  17) without
cardiac events/procedures for more than one year, and
angiographically normal coronary arteries (n  8) (i.e., a
completely smooth coronary lumen with normal caliber), as
well as healthy subjects (n  18). All patients with MI
experienced an acute MI as the first manifestation of CAD.
Six patients in the MI group presented with ST-segment
elevation on the electrocardiogram and were treated with
primary angioplasty and stenting (mean peak creatine phos-
phokinase [CPK] 2,425  3,124 IU/l). The UA group was
treated with percutaneous coronary intervention (PCI)
(88%), all with coronary stents except two patients who
underwent rotational atherectomy only, or medical therapy
(12%). No patient developed CPK-MB elevation following
PCI. Stable CAD patients were diagnosed by a history of
classic angina pectoris, coronary angiography, coronary
revascularization, or MI (Table 1). The normal coronary
artery group underwent coronary angiography because of
chest pain and an abnormal stress test (n  6) or unex-
plained congestive heart failure (n 2). The normal subject
group was composed of young to middle-aged healthy
volunteers.
Patients were entered into the study as outpatients in the
nonhospitalized groups and at hospital admission or arrival
to the cardiac catheterization laboratory (emergently for MI
patients and within 12 h of admission for UA patients).
Fasting venous blood samples were collected in tubes
containing ethylenediamine-tetraacetic acid on entry into
the study and at 30, 120, and 210 days. Blood was also
collected at hospital discharge (mean hospital stay of four
days) in the MI group. The blood was immediately placed
on ice, and plasma was separated by centrifugation at 3,000
rpm for 15 min and stored at 70°C until all assays were
performed concurrently.
Determination of OxLDL autoantibody titers, LDL-IC,
and OxLDL-E06 levels. Chemiluminescence enzyme-
linked immunosorbent assay (ELISA) was used to measure
OxLDL markers at each time point, as previously described
(14–16). All samples for a given analyte were obtained in a
single assay. Each sample was assayed in triplicate, and data
are expressed as relative light units in 100 ms. A high and
low standard plasma was included on each plate of a given
assay to detect potential variations between microtitration
plates. The intra-assay coefficients of variation for all assays
were 6% to 10%.
Titers of immunoglobulin (Ig) G and M autoantibodies,
determined at 1:500 dilutions in human plasma, were
tested for binding to the following antigens representing
different epitopes of OxLDL: 1) malondialdehyde (MDA)-
LDL; 2) copper-oxidized LDL (Cu-OxLDL); 3) oxidized
cholesteryl linoleate-LDL; and 4) 1-palmitoyl-2-(5-
oxovaleryoyl)-phosphatidylcholine (POVPC)-albumin, an
oxidation product of the normal phospholipid 1-palmitoyl-
2-arachidonoyl-phosphatidylcholine. These antigens were
prepared as previously described (16–18).
The baseline levels of OxLDL autoantibodies to the
different model oxidation epitopes were expressed individ-
ually and, to simplify data analysis, as the “mean” OxLDL
titer by summing up the readings of the four different
epitopes and determining the average result. For the
follow-up period, the OxLDL autoantibody data are pre-
sented as the mean percent change compared with the mean
baseline values of the four epitopes.
The LDL-IC was measured as previously described (15).
The extent of circulating, minimally oxidized LDL (termed
Abbreviations and Acronyms
ACS  acute coronary syndromes
ANOVA  analysis of variance
Apo  apolipoprotein
CAD  coronary artery disease
CPK  creatine phosphokinase
Cu-OxLDL  copper-oxidized low-density lipoprotein
HDL  high-density lipoprotein
Ig  immunoglobulin
LDL  low-density lipoprotein
LDL-IC  low-density lipoprotein-immune
complexes
Lp(a)  lipoprotein(a)
MDA-LDL  malondialdehyde-low-density lipoprotein
MI  myocardial infarction
OxLDL  oxidized low-density lipoprotein
OxLDL-E06  oxidized low-density lipoprotein
measured by antibody E06
OxPL  oxidized phospholipids
PC  phosphorylcholine
PCI  percutaneous coronary intervention
POVPC  1-palmitoyl-2-(5-oxovaleryoyl)-
phosphatidylcholine
UA  unstable angina
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OxLDL-E06) was measured using the murine monoclonal
antibody E06, which binds oxidized phospholipids (OxPL),
and the data are expressed as E06 epitopes per apo B-100,
as previously described (15,16).
Lipoprotein assays. Plasma total cholesterol, triglycerides,
and high-density lipoprotein (HDL) were measured by
enzymatic assays. Apolipoprotein A, apo B, and lipopro-
tein(a), or Lp(a), levels were measured by quantitative
immunoprecipitin analysis with commercially available an-
tisera (Diasorin, Stillwater, Minnesota).
Statistical analysis. Statistical analysis was performed with
GraphPad InStat, version 3.01. For baseline categorical
clinical variables, differences were evaluated by the chi-
squared test for independence, and for continuous variables
by one-way analysis of variance (ANOVA). During the
follow-up period, differences between groups at each time
point were evaluated by one-way ANOVA, and differences
within groups by repeated-measures ANOVA with post-
hoc analysis using the Bonferroni multiple comparisons test.
A p value 0.05 was considered statistically significant.
Correlations between various markers of OxLDL were
determined by linear regression analysis. Data are presented
in the text and tables are the mean value  SD and in
figures as the mean value  SEM.
RESULTS
Patient characteristics. The MI and UA groups had a
higher prevalence of hypertension, tobacco use, and beta-
blocker use and a lower prevalence of vitamin E supplement
use (Table 1). At follow-up, one patient in the MI group
underwent rotational atherectomy for in-stent restenosis at
six weeks. Two patients in the UA group had recurrent
angina at 6 and 10 weeks after presentation and underwent
uneventful coronary artery bypass graft surgery. No cardio-
vascular events occurred in the CAD, normal coronary
artery, or normal subject group over seven-month follow-
up.
Baseline lipid and OxLDL parameters. The baseline apo
A-I and HDL levels were significantly different between the
MI (p 0.05) and UA groups (p 0.05), as compared with
the normal subjects (Table 2). At follow-up, 75%, 54%, and
71% of the MI, UA, and CAD patients, respectively, were
on lipid-lowering therapy. In the MI group, LDL choles-
terol levels decreased (120  40 mg/dl to 79  25 mg/dl;
p  0.037) and triglyceride levels increased (93  65 mg/dl
to 224  112 mg/dl; p  0.014) at 30 days and remained at
these levels during follow-up. None of the lipid parameters
changed significantly in the UA, CAD, normal coronary
artery, or normal subject group. The baseline IgG OxLDL
titers (mean of four OxLDL epitopes, as in the Methods
section) were elevated in the MI group compared with the
other groups (p  0.0007) (Table 2). In contrast, the
baseline IgM OxLDL titers (p  0.002) and IgM LDL-IC
(p  0.0001) were significantly higher in the normal
subjects compared with the other groups. The baseline IgG
LDL-IC and OxLDL-E06 were not significantly different
between the groups (Table 2).
Follow-up OxLDL IgM autoantibody titers and IgM
LDL-IC. The individual IgM OxLDL autoantibody titers
(Fig. 1) reflected the trends in the mean OxLDL titers, with
Table 1. Baseline Clinical Characteristics of the Five Study Groups
Acute MI
(n  8)
Unstable Angina
(n  15)
Stable CAD
(n  17)
Normal Coronary
Arteries (n  8)
Normal Subjects
(n  18) p Value
Age (yrs) 58  13 56  13 68  11 58  12 37  7 0.001
Male/female 8/0 11/4 13/4 3/5 11/7 0.13
Coronary risk factors
Hypertension 4 (50) 10 (67) 9 (53) 3 (38) 1 (5) 0.016
Tobacco use 3 (38) 7 (47) 2 (12) 1 (13) 1 (5) 0.008
Diabetes mellitus 2 (25) 3 (20) 4 (24) 1 (13) 0 0.28
LDL cholesterol  130 mg/dl 3 (38) 3 (20) 2 (12) 1 (13) 5 (26) 0.76
HDL cholesterol  35 mg/dl 3 (38) 3 (20) 4 (24) 1 (13) 0 0.11
Medications
Statins 2 (25) 7 (47) 9 (53) 1 (13) 1 (5) 0.25
Other hypocholesterolemic agents 0 0 3 (18) 0 0 0.019
Beta-blockers 2 (25) 8 (53) 4 (24) 1 (13) 1 (5) 0.008
Calcium channel blockers 0 4 (27) 4 (24) 2 (25) 0 0.71
ACE/ARB inhibitors 2 (25) 4 (27) 3 (18) 2 (25) 0 0.71
Aspirin 1 (13) 13 (87) 17 (100) 5 (63) 2 (11) 0.69
Vitamin E 1 (13) 0 5 (29) 1 (13) 5 (26) 0.008
Vitamin C 1 (13) 0 4 (24) 1 (13) 3 (16) 0.11
Multivitamins 0 2 (13) 4 (24) 1 (13) 2 (11) 0.39
Past medical history
MI 0 0 4 (24) 0 0 0.13
CHF 0 1 (7) 1 (6) 2 (26) 0 0.67
PCI 0 2 (13) 3 (18) 0 0 0.80
CABG 0 1 (7) 2 (12) 0 0 0.96
Data are presented as the mean value  SD or number (%) of subjects.
ACE  angiotensin-converting enzyme; ARB  adrenergic receptor blocker; CABG  coronary artery bypass graft surgery; CAD  coronary artery disease; CHF 
congestive heart failure; HDL and LDL  high- and low-density lipoprotein, respectively; MI  myocardial infarction; PCI  percutaneous coronary intervention.
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the largest contribution coming from Cu-OxLDL and
MDA-LDL autoantibodies. To simplify data presentation,
the rest of the analyses are presented as the mean OxLDL
titer made up of all four OxLDL epitopes, as described in
the Methods. The absolute mean IgM OxLDL autoanti-
body titers in the MI and UA groups, which at baseline
were significantly lower than those in the other groups,
showed significant temporal increases compared with their
baseline values (Fig. 2). The IgM OxLDL titers were
significantly different between the groups at 30 days (p 
0.0001) and 210 days (p  0.0001) (Fig. 2A), with the MI
group significantly different from the other groups (p 
0.01). Compared with their own baseline values, intra-
group increases in IgM OxLDL titers were noted in the MI
group at 30 (45%; p 0.001), 120 (17%; p 0.01), and 210
days (26%; p  0.05) and in the UA group at 30 (20%; p 
0.001) and 210 days (15%; p  0.01) (Fig. 2A). Significant
differences between groups in LDL-IC were also noted at
each time point (p  0.001 for all three time points), with
the MI group significantly different from the other groups
(p  0.01) (Fig. 2B). Compared with their own baseline
values, intra-group differences in IgM LDL-IC were noted
in the MI group at 30 (60%; p  0.01) and 120 days (29%;
p  0.05) and in the UA group at 30 days (26%; p  0.01)
(Fig. 2B). No significant changes over time were noted in
the three “control” groups.
Follow-up OxLDL IgG autoantibody titers and IgG
LDL-IC. The absolute mean IgG OxLDL levels remained
significantly elevated in the MI group at all time points (30
days: p  0.0001; 120 days: p  0.036; and 210 days: p 
0.045). Significant differences between groups in IgG Ox-
LDL titers (p  0.026) (Fig. 3A) were noted at 30 days (p
 0.026) and in IgG LDL-IC at 30 (p  0.042), 120 (p 
0.017), and 210 days (p  0.003) (Fig. 3B), with the UA
group having a higher percent change than the other groups
(p  0.05 for both IgG OxLDL and IgG LDL-IC).
Intra-group differences showed greater increases in the UA
group at 30 days compared with the MI group for both IgG
OxLDL autoantibody titers (p  0.001) and IgG LDL-IC
(p  0.05).
Both IgG and IgM OxLDL autoantibodies and LDL-IC
in the MI and UA groups tended to return toward baseline
values but were still elevated at seven months. In general, all
measurements in the three control groups varied by 10%
during the follow-up period.
Follow-up OxLDL-E06 and Lp(a) levels. Oxidized
LDL-E06 levels at baseline were not significantly different
between the groups (Table 2). At follow-up, there were
significant differences between the groups at 30 (p  0.015)
and 210 days (p  0.015) (Fig. 4A). A 54% (p  0.05)
increase in OxLDL-E06 was noted in the MI group at
hospital discharge, approximately four days after the acute
MI. Seven of the eight MI patients had OxLDL-E06
elevations at discharge and at 30 days. In sharp contrast,
there were no significant changes in OxLDL-E06 levels
during the follow-up period in any of the other groups. In
parallel with the rise OxLDL-E06, there was an approxi-
mately twofold rise in Lp(a) in the MI group, which was
significantly different at each time point, compared with the
other groups (Fig. 4B). No significant temporal changes in
Lp(a) were noted in the other groups. Because of the large
variation in baseline absolute Lp(a) values (range 1 to 71
mg/dl), significant differences in the MI group were noted
only at the 120-day time point (p  0.05). However, six of
the eight MI patients had increases in Lp(a). In comparison,
there was a reduction of 30% in plasma LDL cholesterol
(p  0.029 at 30 days compared with other groups) (Fig.
4C), as well as a 27% reduction in plasma apo B (p  0.05;
data not shown).
Correlation between OxLDL-E06 and Lp(a). Plasma
OxLDL-E06 levels correlated exceedingly well with plasma
Lp(a) levels (Fig. 5). In the entire cohort of patients at each
Table 2. Baseline Lipid and OxLDL Parameters
Acute MI
Unstable
Angina
Stable
CAD
Normal Coronary
Arteries
Normal
Subjects p Value
Lipid parameters (mg/dl)
Total cholesterol 184  42 166  35 179  35 169  48 182  37 0.67
LDL cholesterol 120  40 98  31 95  29 98  37 106  82 0.62
HDL cholesterol 39  9 41  9 49  18 52  18 57  13 0.009
Triglycerides 93  65 138  87 186  158 91  64 96  67 0.07
Apolipoprotein A 136  40 110  29 99  17 135  32 144  30 0.003
Apolipoprotein B 93  16 95  21 94  14 88  32 92  25 0.97
Lp (a) 15  16 26  19 32  23 37  33 28  22 0.37
OxLDL parameters (RLU)
Anti-OxLDL IgG* 6602  5699 2169  2614 3036  3159 2208  3159 2407  3077* 0.0007
Anti-OxLDL IgM* 9626  10546 7541  6707 6811  5866 11719  10486 13141  14830 0.002
IC-IgM 11010  6398 8194  3096 8658  3032 10706  3665 16352  5552 0.0001
IC-IgG 10609  4662 8007  3667 11554  5126 7617  3504 9246  3957 0.11
OxLDL-E06† 0.29  0.16 0.47  0.30 0.46  0.28 0.42  0.33 0.42  0.35 0.67
*OxLDL IgG and IgM are the mean levels for the four individual OxLDL epitopes. †OxLDL-E06 is expressed as the number of E06 epitopes/apc B-100. Data are presented
as the mean value  SD.
IC  immune complex; Ig  immunoglobulin; Lp(a)  Lipoprotein (a); OxLDL  oxidized low-density lipoprotein; RLU  relative light units; other abbreviations as in
Table 1.
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Figure 1. Percent change from baseline in individual immunoglobulin (Ig)M oxidized low-density lipoprotein (OxLDL) autoantibody titers. The p values at the 30-, 120-, and 210-day labels represent
differences between groups at each time point. **p  0.01 for differences within individuals groups. CAD  coronary artery disease; Cu-LDL  copper oxidized low-density lipoprotein; MDA-LDL 
malondialdehyde-low-density lipoprotein; MI  myocardial infarction; POVPC  1-palmitoyl-2-(5-oxovaleryoyl)-phosphatidylcholine.
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Figure 2. Percent change from baseline in mean immunoglobulin (Ig)M oxidized low-density lipoprotein (OxLDL) autoantibody titers (A) and IgM
low-density lipoprotein (LDL)-immune complexes (B). The p values at the 30-, 120-, and 210-day labels represent differences between groups at each time
point. *p 0.05, **p 0.01, and ***p 0.001 for differences within individual groups. CAD coronary artery disease; MImyocardial infarction; UNSA
 unstable angina.
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Figure 3. Percent change from baseline in mean immunoglobulin (Ig)G oxidized low-density lipoprotein (OxLDL) autoantibody titers (A) and IgG
low-density lipoprotein (LDL)-immune complexes (B). The p values at the 30-, 120-, and 210-day labels represent differences between groups at each time
point. *p  0.05, **p  0.01, and ***p  0.001 for differences within individual groups. CAD  coronary artery disease; MI  myocardial infarction;
UNSA  unstable angina.
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Figure 4. Percent change from baseline in oxidized low-density lipoprotein measured by antibody E06 (OxLDL-E06) (A), lipoprotein(a) (Lp[a]) (B), and
low-density lipoprotein (LDL) cholesterol levels (C). The p values at the 30-, 120-, and 210-day labels represent differences between groups at each time
point. *p  0.05 for differences within individual groups. CAD  coronary artery disease; MI  myocardial infarction.
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time point, very strong correlations were noted between
OxLDL-E06 and Lp(a) (baseline: r 0.90, p 0.0001; 30
days: r  0.91, p  0.0001; 120 days: r  0.90, p  0.0001;
210 days: r 0.97, p 0.0001), as well as for the entire cohort
of patients and samples at all time points combined (r 0.91,
p 0.0001) (Fig. 5). Similar strong correlations existed within
individual groups, including the normal subjects (r 0.97, p
0.0001 for normal subjects at baseline sample).
Correlations among OxLDL autoantibodies. To assess
the inter-relationships between OxLDL autoantibodies, we
performed a regression analysis by pooling the data points
for all five patient groups at each of the time points for each
individual autoantibody titer (Table 3). Very strong to
moderate correlations were seen among all OxLDL auto-
antibodies, particularly between Cu-OxLDL and both
POVPC and MDA-LDL. Interestingly, all OxLDL auto-
antibodies and LDL-IC correlated with each other to some
extent. There were no significant correlations between
OxLDL-E06 and any OxLDL autoantibody measurement,
nor with total, LDL, or HDL cholesterol. There was also
no significant correlation between peak or total CPK levels
and any OxLDL parameter at any time point.
DISCUSSION
In this study, we addressed the question of whether circu-
lating markers of OxLDL reflect ACS, a situation in which
atherosclerotic plaque disruption is known to occur. We
demonstrate prospectively, for the first time, that indirect
and direct plasma markers of OxLDL show significant
temporal elevations following ACS, particularly in patients
with acute MI, but not in patients with stable CAD or in
subjects without CAD. In addition, we demonstrate the
novel observation of a very strong correlation between
plasma Lp(a) levels and OxLDL-E06 levels, which repre-
sent OxPL epitopes, suggesting a physiologic (or patho-
physiologic) role for Lp(a) in the transport of OxPL.
Baseline IgG OxLDL titers were elevated at baseline and
follow-up in the acute MI group, consistent with a previous
study of patients with a healed MI (19). Baseline IgM
OxLDL titers and LDL-IC were lower, interestingly, in the
three groups of patients with CAD, compared with healthy
subjects, but rose significantly at follow-up only in the ACS
groups. Lower plasma IgM OxLDL autoantibodies have
been previously noted in patients with a previous MI (19),
stable CAD (19,20), and borderline hypertension (15) and
have been inversely associated with increased carotid intima
thickness (20). It has been speculated that OxLDL may
form immune complexes with preexisting autoantibodies,
which act as vehicles for clearance of antigen (10,13,14).
Thus, lower IgM titers in CAD patients may actually reflect
the consequence of a protective effect.
During the follow-up period, increases in IgM OxLDL
autoantibody titers, despite the fact that they were signifi-
cantly lower in the MI, UA, and CAD groups, were most
dramatic in the MI group. These immune responses likely
reflect immune activation due to exposure of OxLDL and
oxidation-specific epitopes potentially released from both
disrupted plaques and, in the case of acute MI, potential
additional sources derived from myocyte cell membranes of
apoptotic or dying cells, which contain OxPL (18). These
data are also remarkable for the consistency of titers noted at
four time points over a seven-month period in normal
subjects, an observation that has not been previously re-
ported.
Oxidized phospholipids are a prominent component of
minimally modified LDL and OxLDL and have many
pro-inflammatory and pro-atherogenic properties (21). The
natural autoantibody E06, cloned from apo E-/- mice, binds
to OxPL containing the phosphorylcholine (PC) head
Figure 5. Correlation between plasma lipoprotein(a) (Lp[a]) and oxidized
low-density lipoprotein measured by antibody E06 (OxLDL-E06) levels,
defined as the ratio of E06 to apolipoprotein (apo) B-100 and measured as
relative light units, as described in the Methods section. The results from
each time point for all of the patients are combined and analyzed
simultaneously.
Table 3. Correlations (“R-value”) Among OxLDL
Autoantibodies and LDL-IC
IgM IgG
OxLDL autoantibodies
Cu-OxLDL vs. POVPC 0.79 (0.0001) 0.70 (0.0001)
Cu-OxLDL vs. MDA-LDL 0.72 (0.0001) 0.59 (0.0001)
Cu-OxLDL vs. OxChol linoleate 0.56 (0.0001) 0.12 (0.056)
MDA-LDL vs. OxChol linoleate 0.48 (0.0001) 0.23 (0.0002)
MDA-LDL vs. POVPC 0.42 (0.0001) 0.39 (0.0001)
OxChol linoleate vs. POVPC 0.36 (0.0001) 0.22 (0.047)
LDL-IC
Cu-OxLDL vs. LDL-IC 0.68 (0.0001) 0.64 (0.0001)
POVPC vs. LDL-IC 0.66 (0.0001) 0.41 (0.0001)
MDA-LDL vs. LDL-IC 0.47 (0.0001) 0.61 (0.0001)
OxChol linoleate vs. LDL-IC 0.30 (0.0001) 0.23 (0.05)
Data are presented as the correlation coefficient (r), with the p value in parentheses.
Cu-OxLDL  copper-oxidized low-density lipoprotein; MDA  malondialde-
hyde; OxChol  oxidized cholesterol; POVPC  1-palmitoyl-2-(5-oxovaleryoyl)-
phosphatidylcholine; other abbreviations as in Table 2.
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group, but not to native unoxidized PC-containing phos-
pholipids (17), and has been used to develop a chemilumi-
nescent ELISA to detect circulating OxPL (16). E06 and
similar E0 autoantibodies were found to be structurally and
functionally identical to classic “natural” T15 anti-PC anti-
bodies, which provide protection from pneumococcal infec-
tion (22). In addition, a proportion of so-called “antiphos-
pholipid antibodies,” which are associated with thrombotic
disorders, are actually directed to OxPL, such as oxidized
cardiolipin, and cross-react with OxLDL (23). The rise in
OxLDL-E06 in the first month in the MI group, as
opposed to the other groups, suggests that there is contin-
ued release and/or generation of these OxPL epitopes,
possibly from both disrupted atherosclerotic plaques and the
injured myocardium (24,25). Similarly, isoprostanes, stable
end-products of arachidonic acid oxidation, are elevated in
patients with acute MI treated with angioplasty (26). In
addition, it has been recently appreciated that patients with
acute MI may have multiple disrupted plaques in arteries
other than the infarct-related artery (27), which may release
OxPL.
Recent studies measuring circulating OxLDL using dif-
ferent antibodies and assay procedures have shown an
association with CAD (reviewed in Tsimikas and Witztum
[24]). By using the antibody DLH3, which detects an
OxPL epitope immunologically similar to that recognized
by E06 (16), Ehara et al. (25) showed that circulating
OxLDL-DLH3 levels, as measured on isolated LDL rather
than plasma, reflected the presence of immunochemically
detected OxLDL in coronary atherectomy specimens and
appeared to differentiate, to some extent, the severity of the
underlying clinical presentation. Other studies by Holvoet
et al. (28) using antibodies to measure “fully oxidized” LDL,
such as MDA-LDL and Cu-OxLDL, showed that Ox-
LDL measured in the emergency room setting is a strong
predictor of the presence of ACS, in conjunction with
troponin measurements. Because it is not precisely known
which OxLDL markers are more relevant to specific disease
states, the current work significantly expands on these
observations by showing a consistent association of ACS
with a comprehensive panel of 11 OxLDL markers, with a
prospective follow-up study period. In addition, it provides
plausible, novel pathophysiologic links between plaque rup-
ture, OxLDL, and atherogenicity of Lp(a).
The observation that OxLDL-E06 and Lp(a) plasma
levels correlate exceedingly well is of considerable interest.
Although basal Lp(a) levels are primarily genetically deter-
mined, Lp(a) appears to act as an acute-phase reactant
under some situations (29). Indeed, in our study, Lp(a)
levels increased approximately twofold after MI, consistent
with a previous report (30). The observation that OxPL and
Lp(a) correlate so closely implies that Lp(a) has a very
strong affinity for OxPL, which are toxic oxidative byprod-
ucts derived from sources of cellular injury such as plaque
disruption and myocyte death. These OxPL may be pref-
erentially transferred to and sequestered by Lp(a) after being
released into the circulation. Preliminary data from our
laboratory have shown that the majority of E06 epitopes in
the circulation are carried on Lp(a), as opposed to other apo
B-containing lipoproteins (unpublished observations of C.
Bergmark, J. L. Witztum, and S. Tsimikas, 2002). It has
been previously speculated that Lp(a) acts as a scavenger of
OxPL, as it contains an unusually high content and activity
of platelet-activating factor acetylhydrolase, an enzyme with
the capacity to degrade OxPL (29,31). Thus, according to
this hypothesis, the enhanced levels of both OxPL and
Lp(a) may be a reflection of enhanced oxidative stress. It is
possible that the same set of cytokines that lead to upregu-
lation of other acute-phase reactants might also lead to
upregulation of Lp(a). Because a similarly strong OxLDL-
E06/Lp(a) correlation exists for normal subjects, this also
suggests that OxPL are continually released during normal
cellular homeostasis, and their plasma level will, to some
extent, depend on Lp(a) levels. Thus, the pro-atherogenic
properties of Lp(a), particularly when plasma levels are
elevated, may be due to its predilection for the vessel wall
while accompanied by these oxidative byproducts, resulting
in enhanced inflammation and progression of atherosclero-
sis. Indeed, Lp(a) has been documented to exist in larger
amounts in unstable coronary plaques compared with stable
plaques and to co-localize with macrophages (32). Confir-
mation of these hypotheses awaits further studies.
Study limitations. First, a relatively small number of pa-
tients were studied in each group. However, we measured
11 parameters of OxLDL in each blood sample, and
changes were noted only in the ACS groups. Second, the
majority of patients with ACS underwent PCI, which could
have potentially induced increases in OxLDL markers, as
PCI has been associated with lipid peroxidation, as noted
earlier. Although PCI may have contributed to some of the
effect, the data showed that MI patients had more dramatic
responses, primarily IgM, whereas the UA group had
primarily IgG responses, arguing against this as the sole
explanation. Plaque disruption is a common phenomenon in
both PCI and spontaneous plaque rupture, making it
difficult to dissect out the individual contributions of each.
Larger studies in patients with stable angina are required to
address the question of whether PCI induces short- or
long-term changes in OxLDL markers. Third, because we
do not have access to pre-presentation OxLDL markers,
one may argue that these are epiphenomena of plaque
disruption, rather than direct contributors. Although this
study cannot address this issue, previous studies (25,28)
have clearly documented a direct relationship between
OxLDL and the clinical presentation. The rise and fall of
OxLDL markers seen in this study may, in fact, represent
both the plaque rupture and healing phase of ACS.
Clinical implications. The dramatic changes in OxLDL
markers in patients presenting with ACS suggest that
OxLDL markers may be useful in understanding plaque
destabilization. Measurement of plasma markers of OxLDL
may provide a noninvasive window to study atherosclerotic
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lesions and should stimulate further research to assess
whether these markers provide an enhanced diagnosis, risk
stratification, and possibly prognostic information.
Conclusions. This study demonstrates that circulating Ox-
LDL markers seem to reflect plaque disruption and oxida-
tive stress associated with ACS. In addition, these findings
support the hypothesis that in this setting, Lp(a) may act as
an acute-phase reactant and scavenge OxPL, resulting in
enhanced atherogenicity. Prospective studies in larger
groups of patients are required to evaluate whether these
measurements provide long-term prognostic information
and to assess the effect of therapeutic interventions on
OxLDL markers.
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